An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Daina, A., & Zoete, V. (2016) · ChemMedChem · doi:10.1002/cmdc.201600182 · Cited by 2,549
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
Self-citationOpportunities and obstacles for deep learning in biology and medicine
Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., Ferrero, E., Agapow, P.-M., Zietz, M., Hoffman, M. M., et al. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0387 · Cited by 2,310
Deep reinforcement learning for de novo drug design
Popova, M., Isayev, O., & Tropsha, A. (2018) · Science Advances · doi:10.1126/sciadv.aap7885 · Cited by 1,182
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
BDDCS, the Rule of 5 and drugability
Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.007 · Cited by 892
ADMET modeling approaches in drug discovery
Ferreira, L. L. G., & Andricopulo, A. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.015 · Cited by 825
Low Data Drug Discovery with One-Shot Learning
Altae-Tran, H., Ramsundar, B., Pappu, A. S., & Pande, V. (2017) · ACS Central Science · doi:10.1021/acscentsci.6b00367 · Cited by 799
Wang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., Zhang, R., Zhu, J., Ren, Y., Tan, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz981 · Cited by 794
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
3D bioprinting of tissues and organs for regenerative medicine
Vijayavenkataraman, S., Yan, W.-C., Lu, W. F., Wang, C.-H., & Fuh, J. Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.004 · Cited by 630
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629
Transition-Metal-Catalyzed C–H Bond Activation for the Formation of C–C Bonds in Complex Molecules
Docherty, J. H., Lister, T. M., Mcarthur, G., Findlay, M. T., Domingo-Legarda, P., Kenyon, J., Choudhary, S., & Larrosa, I. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00888 · Cited by 593
Use of Zebrafish in Drug Discovery Toxicology
Cassar, S., Adatto, I., Freeman, J. L., Gamse, J. T., Iturria, I., Lawrence, C., Muriana, A., Peterson, R. T., Van Cruchten, S., & Zon, L. I. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00335 · Cited by 561
Poly(lactic acid) blends in biomedical applications
Saini, P., Arora, M., & Kumar, M. N. V. R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.014 · Cited by 549
New developments in anti-malarial target candidate and product profiles
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R., Kaszubska, W., Macintyre, F., Mazzuri, S., Möhrle, J. J., & Wells, T. N. C. (2017) · Malaria Journal · doi:10.1186/s12936-016-1675-x · Cited by 520
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Synthesis and Biological Application of Polylactic Acid
Li, G., Zhao, M., Xu, F., Yang, B., Li, X., Meng, X., Teng, L., Sun, F., & Li, Y. (2020) · Molecules · doi:10.3390/molecules25215023 · Cited by 492
Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455
“Drug research and development is a complex, expensive, time-consuming procedure and has a high attrition rate (1).”
BackgroundInduced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Fsp3: A new parameter for drug-likeness
Wei, W., Cherukupalli, S., Jing, L., Liu, X., & Zhan, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.017 · Cited by 421
Pound, P., & Ritskes-Hoitinga, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1678-1 · Cited by 419
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Self-citationBio-inks for 3D bioprinting: recent advances and future prospects
Donderwinkel, I., van Hest, J. C. M., & Cameron, N. R. (2017) · Polymer Chemistry · doi:10.1039/c7py00826k · Cited by 378
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Medicine in the Fourth Dimension
Cederroth, C. R., Albrecht, U., Bass, J., Brown, S. A., Dyhrfjeld-Johnsen, J., Gachon, F., Green, C. B., Hastings, M. H., Helfrich-Förster, C., Hogenesch, J. B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.019 · Cited by 359
A Practical Guide to the Design of Molecular Crystals
Corpinot, M. K., & Bučar, D.-K. (2019) · Crystal Growth & Design · doi:10.1021/acs.cgd.8b00972 · Cited by 348
Zushin, P.-J. H., Mukherjee, S., & Wu, J. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175824 · Cited by 347
Mechanisms of increased bioavailability through amorphous solid dispersions: a review
Schittny, A., Huwyler, J., & Puchkov, M. (2020) · Drug Delivery · doi:10.1080/10717544.2019.1704940 · Cited by 343
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction
Myung, Y., de Sá, A. G. C., & Ascher, D. B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae254 · Cited by 337
The Blood–Brain Barrier (BBB) Score
Gupta, M., Lee, H. J., Barden, C. J., & Weaver, D. F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01220 · Cited by 332
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Ozbolat, V., Sosnoski, D., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 313
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Self-citationMarx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“A compilation for oral small molecules from four large pharmaceutical companies revealed an attrition rate of 35% in phase II due to efficacy concerns (Waring et al., 2015).”
Self-citationDosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy
Dallmann, R., Okyar, A., & Lévi, F. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.004 · Cited by 293
Modulators of 14-3-3 Protein–Protein Interactions
Stevers, L. M., Sijbesma, E., Botta, M., MacKintosh, C., Obsil, T., Landrieu, I., Cau, Y., Wilson, A. J., Karawajczyk, A., Eickhoff, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00574 · Cited by 279
Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
vNN Web Server for ADMET Predictions
Schyman, P., Liu, R., Desai, V., & Wallqvist, A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00889 · Cited by 254
Butler, M. S., Gigante, V., Sati, H., Paulin, S., Al-Sulaiman, L., Rex, J. H., Fernandes, P., Arias, C. A., Paul, M., Thwaites, G. E., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01991-21 · Cited by 252
Open access in silico tools to predict the ADMET profiling of drug candidates
Kar, S., & Leszczynski, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1798926 · Cited by 250
Few-Shot Graph Learning for Molecular Property Prediction
Guo, Z., Zhang, C., Yu, W., Herr, J. E., Wiest, O., Jiang, M., & Chawla, N. V. (2021) · International World Wide Web Conference (WWW) · doi:10.1145/3442381.3450112 · Cited by 242
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines
Daley, G. Q., Hyun, I., Apperley, J. F., Barker, R. A., Benvenisty, N., Bredenoord, A. L., Breuer, C. K., Caulfield, T., Cedars, M. I., Frey-Vasconcells, J., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.05.001 · Cited by 222
Marx, U. (2020) · ALTEX · doi:10.14573/altex.2001241 · Cited by 218
Three‐dimensional cell culture models for anticancer drug screening: Worth the effort?
Verjans, E., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26052 · Cited by 212
Adversarial Threshold Neural Computer for Molecular de Novo Design
Putin, E., Asadulaev, A., Vanhaelen, Q., Ivanenkov, Y., Aladinskaya, A. V., Aliper, A., & Zhavoronkov, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01137 · Cited by 211
Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study
Bitew, M., Desalegn, T., Demissie, T. B., Belayneh, A., Endale, M., & Eswaramoorthy, R. (2021) · PLOS ONE · doi:10.1371/journal.pone.0260853 · Cited by 197
Bioprinting towards physiologically relevant tissue models for pharmaceutics
Peng, W., Unutmaz, D., & Ozbolat, I. T. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.05.013 · Cited by 196
Nagoor Meeran, M. F., Goyal, S. N., Suchal, K., Sharma, C., Patil, C. R., & Ojha, S. K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00892 · Cited by 196
Toxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Gu, Y., Yu, Z., Wang, Y., Chen, L., Lou, C., Yang, C., Li, W., Liu, G., & Tang, Y. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae298 · Cited by 188
Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Computational prediction of formulation strategies for beyond-rule-of-5 compounds
Bergström, C. A. S., Charman, W. N., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.005 · Cited by 187
Docking techniques in pharmacology: How much promising?
Gupta, M., Sharma, R., & Kumar, A. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.06.005 · Cited by 186
Phenome-wide association studies across large population cohorts support drug target validation
Diogo, D., Tian, C., Franklin, C. S., Alanne-Kinnunen, M., March, M., Spencer, C. C. A., Vangjeli, C., Weale, M. E., Mattsson, H., Kilpeläinen, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06540-3 · Cited by 186
Andrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M., Freitas, C. S., Marcon, R., & Calixto, J. B. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165646 · Cited by 184
The many roles of molecular complexity in drug discovery
Méndez-Lucio, O., & Medina-Franco, J. L. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.009 · Cited by 180
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Self-citationTarget-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Leeson, P. D., Bento, A. P., Gaulton, A., Hersey, A., Manners, E. J., Radoux, C. J., & Leach, A. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00416 · Cited by 176
Self-citationDevelopment of Safe Drugs: The hERG Challenge
Kalyaanamoorthy, S., & Barakat, K. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21445 · Cited by 174
The Symbiotic Relationship Between Drug Discovery and Organic Chemistry
Grygorenko, O. O., Volochnyuk, D. M., Ryabukhin, S. V., & Judd, D. B. (2020) · Chemistry – A European Journal · doi:10.1002/chem.201903232 · Cited by 174
Methyl-containing pharmaceuticals: Methylation in drug design
Sun, S., & Fu, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.016 · Cited by 174
Derivation of adult canine intestinal organoids for translational research in gastroenterology
Chandra, L. C., Borcherding, D. C., Kingsbury, D. D., Atherly, T. A., Ambrosini, Y. M., Bourgois‐Mochel, A., Wang, Y., Kimber, M. J., Qi, Y., Wang, Q., et al. (2019) · BMC Biology · doi:10.1186/s12915-019-0652-6 · Cited by 174
Potential and Therapeutic Roles of Diosmin in Human Diseases
Huwait, E. A., & Mobashir, M. (2022) · Biomedicines · doi:10.3390/biomedicines10051076 · Cited by 174
Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
Lin, L., & Wong, H. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040041 · Cited by 172
Hemmerich, J., & Ecker, G. F. (2020) · WIREs Computational Molecular Science · doi:10.1002/wcms.1475 · Cited by 169
Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges
Wang, Y. I., Carmona, C., Hickman, J. J., & Shuler, M. L. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701000 · Cited by 167
Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity
Zakaria, Z. Z., Benslimane, F. M., Nasrallah, G. K., Shurbaji, S., Younes, N., Mraiche, F., Da'as, S. I., & Yalcin, H. C. (2018) · BioMed Research International · doi:10.1155/2018/1642684 · Cited by 166
Fischer, A., Sellner, M., Neranjan, S., Smieško, M., & Lill, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103626 · Cited by 165
Drug Design—Past, Present, Future
Doytchinova, I. A. (2022) · Molecules · doi:10.3390/molecules27051496 · Cited by 165
Automated De Novo Drug Design: Are We Nearly There Yet?
Schneider, G., & Clark, D. E. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201814681 · Cited by 164
Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update
Maher, S., Brayden, D. J., Casettari, L., & Illum, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11010041 · Cited by 163
Zhang, J., Li, H., Zhang, Y., Huang, J., Ren, L., Zhang, C., Zou, Q., & Zhang, Y. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf533 · Cited by 163
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
Clark, M., & Steger-Hartmann, T. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.04.018 · Cited by 162
Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., Patterson, N. L., & McMullen, J. R. (2018) · Physiological Reviews · doi:10.1152/physrev.00043.2016 · Cited by 160
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 160
Artificial Intelligence in Pharmaceutical Sciences
Lu, M., Yin, J., Zhu, Q., Lin, G., Mou, M., Liu, F., Pan, Z., You, N., Lian, X., Li, F., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.01.014 · Cited by 157
ADMETboost: a web server for accurate ADMET prediction
Tian, H., Ketkar, R., & Tao, P. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05373-8 · Cited by 155
In silico prediction of novel therapeutic targets using gene–disease association data
Ferrero, E., Dunham, I., & Sanséau, P. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1285-6 · Cited by 152
Alexander-Dann, B., Pruteanu, L.-L., Oerton, E., Sharma, N., Berindan‐Neagoe, I., Módos, D., & Bender, A. (2018) · Molecular Omics · doi:10.1039/c8mo00042e · Cited by 149
Enriching screening libraries with bioactive fragment space
Zhang, N., & Zhao, H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.013 · Cited by 148
Next generation organoids for biomedical research and applications
Lou, Y., & Leung, A. W. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.10.005 · Cited by 143
Applications of Microfluidics and Organ-on-a-Chip in Cancer Research
Regmi, S., Poudel, C., Adhikari, R., & Luo, K. Q. (2022) · Biosensors · doi:10.3390/bios12070459 · Cited by 143
Learning Graph-Level Representation for Drug DiscoveryPreprint
Li, J., Cai, D., & He, X. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1709.03741 · Cited by 143
Is there enough focus on lipophilicity in drug discovery?
Planey, S. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1691995 · Cited by 143
Archer, C. R., Sargeant, R., Basak, J., Pilling, J. E., Barnes, J. R., & Pointon, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28393-y · Cited by 141
Tinworth, C. P., & Young, R. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01596 · Cited by 141
Binding kinetics of ligands acting at GPCRs
Sykes, D. A., Stoddart, L. A., Kilpatrick, L. E., & Hill, S. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.018 · Cited by 138
Moingeon, P. E., Kuenemann, M. A., & Guedj, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.006 · Cited by 138
An αv‐RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities
Hatley, R. J. D., Macdonald, S. J. F., Slack, R. J., Le, J., Ludbrook, S. B., & Lukey, P. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707948 · Cited by 137
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.